PAIN & ORTHO · KASDAP HEALTHCARE
Musculoskeletal conditions and chronic pain represent India's largest driver of disability. This guide covers key therapeutic categories, clinical considerations, and quality standards in pain and orthopaedic pharmacotherapy.
The Musculoskeletal Disease Burden in India
Musculoskeletal disorders — encompassing arthritis, osteoporosis, back pain, sports injuries, and rheumatological conditions — are among the leading causes of disability in India. The World Health Organization estimates that musculoskeletal conditions affect 1.71 billion people globally, with India carrying a disproportionate burden due to its large elderly population, high rates of nutritional deficiencies, and significant occupational and agricultural injury rates.
Rheumatoid arthritis alone affects an estimated 10 million Indians, while osteoarthritis — the most common joint disease — is prevalent in over 15% of the population above 60 years. The economic burden of musculoskeletal conditions in India runs into tens of thousands of crores annually, driven by productivity loss, healthcare costs, and disability.
NSAIDs: The Backbone of Pain Management
Non-selective NSAIDs
Diclofenac, Ibuprofen, Naproxen, and Ketoprofen are widely prescribed for acute musculoskeletal pain, post-operative pain, and inflammatory conditions. They work by inhibiting both COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and producing analgesic, anti-inflammatory, and antipyretic effects.
The main clinical limitations of non-selective NSAIDs are GI adverse effects (gastric mucosal damage, peptic ulceration) and renal toxicity with long-term use. Co-prescription of a PPI is recommended for patients requiring long-term NSAID therapy, particularly the elderly and those with prior GI history.
Selective COX-2 Inhibitors (Coxibs)
Celecoxib and Etoricoxib selectively inhibit the COX-2 enzyme, providing anti-inflammatory and analgesic effects with significantly reduced GI risk compared to non-selective NSAIDs. They are preferred in patients at high GI risk but require caution in patients with cardiovascular disease due to prothrombotic potential.
Aceclofenac: India's Most Prescribed NSAID
Aceclofenac has a distinct position in the Indian market — it is one of the most commonly prescribed NSAIDs by Indian orthopaedic surgeons and rheumatologists. It offers a balanced COX inhibition profile with good analgesic efficacy and reportedly better GI tolerability than Diclofenac, though evidence continues to evolve.
Paracetamol: The Universal Analgesic
Paracetamol (Acetaminophen) remains the most widely used analgesic globally, valued for its safety, affordability, and efficacy for mild-to-moderate pain. It is first-line for osteoarthritis pain in patients without significant inflammatory disease, and is frequently combined with NSAIDs or opioids for enhanced pain relief.
Disease-Modifying Antirheumatic Drugs (DMARDs)
DMARDs are the cornerstone of rheumatoid arthritis management, disease management aimed at suppressing the underlying inflammatory process and preventing joint damage. The treat-to-target approach, aiming for low disease activity or remission, has transformed rheumatoid arthritis outcomes.
Conventional Synthetic DMARDs (csDMARDs)
- Methotrexate: The anchor DMARD in rheumatoid arthritis. Weekly low-dose oral Methotrexate is the first-line DMARD in most guidelines, often combined with folic acid supplementation to minimise GI and hepatic side effects
- Hydroxychloroquine: Used as monotherapy in mild RA and as a combination partner. Requires annual ophthalmological monitoring for retinal toxicity
- Sulfasalazine: Effective DMARD, particularly in combination regimens. Useful in seronegative arthritis and enteropathic arthritis
- Leflunomide: An alternative to Methotrexate with comparable efficacy; requires monitoring for hepatotoxicity and hypertension
Muscle Relaxants: Managing Spasm and Spasticity
Muscle spasm is a common component of acute musculoskeletal pain, and spasticity is a significant complication of neurological conditions affecting the musculoskeletal system. Key muscle relaxant categories include:
- Cyclobenzaprine: Most commonly used centrally-acting muscle relaxant for acute muscle spasm
- Tizanidine: Alpha-2 agonist used for spasticity in multiple sclerosis and stroke; also used in chronic musculoskeletal pain
- Chlorzoxazone: Widely used in India for acute musculoskeletal pain in combination with analgesics
- Baclofen: Primary agent for spasticity in upper motor neuron conditions including stroke and spinal cord injury
- Methocarbamol and Carisoprodol: Used for acute musculoskeletal spasm with varying evidence bases
Bone Health: Prevention and Treatment of Osteoporosis
Osteoporosis affects an estimated 50 million Indians, with women disproportionately affected post-menopause. The economic and social burden of osteoporotic fractures — particularly hip fractures in the elderly — is enormous. Pharmacological management includes:
- Calcium and Vitamin D3: The foundation of all osteoporosis prevention and treatment programmes
- Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic acid): First-line pharmacological agents for established osteoporosis
- Raloxifene: Selective oestrogen receptor modulator (SERM) for postmenopausal osteoporosis with concurrent breast cancer risk reduction
- Teriparatide: Anabolic agent for severe osteoporosis with high fracture risk
Kasdap Healthcare's Pain, Ortho & Rheumatology Portfolio
Kasdap Healthcare provides a comprehensive pain and ortho portfolio including NSAIDs, DMARDs, muscle relaxants, bone health supplements, and combination products — all manufactured under WHO-GMP aligned protocols and available through our pan-India distribution network.
Explore Kasdap's Pain, Ortho & Rheumatology range
